Laila Rigmor Evjensvold
Inventor & Clinical Expert · Aesthetic Nurse
Identified the clinical limitations that led to the development of DMC, based on years of hands-on work in aesthetic medicine
Developed in Norway · Patent granted by EPO and USPTO
Designed to be safe, efficient and predictable
Diamond MesoCannula introduces a mechanical approach to injectable precision, enabling consistent depth and distribution through a controlled multi-needle system
A precision cannula for mesotherapy and advanced injection techniques
Controlled dermal delivery with complete regularity and predictable injection depth
Enabling standardized procedures, reducing risk of complications and increasing patient safety
Scalable beyond mesotherapy, facilitating future product lines
The underlying geometry is not tied to a single procedure, enabling cross-disciplinary adoption and long-term commercial value.
Originating from clinical practice
Diamond MesoCannula was developed by Laila Evjensvold through 2 decades of hands-on clinical work in aesthetic medicine.
Over time a recurring issue became clear. Even with experience and skill, achieving consistent depth, volume and symmetry in skin booster treatments remained challenging.
Throughout her career as a cosmetic nurse with vast experience she searched and waited for suitable devices for this purpose to appear.
Rather than relying on technique alone, the idea was to solve the problem structurally. That insight led to the development of a multi-needle cannula system, designed to make precision more predictable.
The intention of the device is to achieve a natural, healthy result maintaining the individual physiognomy without overfilling.
2007
Clinical insight
Laila Evjensvold identifies limitations in existing cannula solutions
2013
Market evaluation
Evaluation of existing designs confirms the absence of a product addressing the identified need.
2019
Patent application
Initial patent application submitted. Following Norwegian rejection, the concept is further developed
2025
Patent granted
Patent granted by the EPO (European Patent Office), followed by the USPTO (United States Patent and Trademark Office) in 2026
Precision should not depend on the operator
Despite extensive clinical experience, most skin booster treatments remain operator-dependent. Injection depth, volume control and symmetry rely on manual technique, repetition and individual judgement.
Even among skilled practitioners, this introduces variation between treatments. Small differences in angle, pressure or spacing can significantly affect distribution and consistency. This is particularly true across larger treatment areas or anatomically sensitive regions.
This challenge is not a question of competence. It is a structural limitation in current injection techniques. When precision is achieved manually, repeatability becomes difficult to guarantee.
Consistency cannot rely on experience alone. Precision could be designed into the method itself.
Designing precision as a mechanical system
Diamond MesoCannula represents a system-level response to this problem.
Controlled penetration depth
Simultaneous multi-needle delivery
Fixed spacing for symmetrical distribution
Patent protection
Diamond MesoCannula was granted patent, design and trademark protection by the EPO in 2025 and USPTO in 2026, recognizing both novelty and inventive steps.
Next step
Diamond MesoCannula is entering the next phase of development, with the goal of building a functional prototype and preparing for initial clinical evaluation. The project is open to dialogue with investors and partners interested in contributing to further development, validation and commercialization.
Meet the team
Jens Ola Evjensvold
Technical Advisor · General & Vascular Surgeon
Contributes surgical and anatomical expertise
Trine Evjensvold
CEO & Clinical Lead · Dentist
Leads the clinical and strategic development of the system
Truls Evjensvold
Medical Advisor · Orthopedic Surgeon
Supports clinical testing and evaluation
Let’s talk about the next step
Diamond MesoCannula is currently in continued development for clinical validation. We welcome dialogue with clinicians, partners and investors with a clear interest in clinical evaluation, development or commercialization.
Get in touch